Lithium treatment arrests the development of neurofibrillary tangles in mutant tau transgenic mice with advanced neurofibrillary pathology.

Neuropathological stageing of Alzheimer-related changes.

Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668 · see citing works

A molecular mechanism for the effect of lithium on development.

Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,305 · see citing works

Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders

Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · see citing works

GSK-3: tricks of the trade for a multi-tasking kinase

Doble, B. W., & Woodgett, J. R. (2003) · Journal of Cell Science · doi:10.1242/jcs.00384 · Cited by 2,084 · see citing works

Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function

SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014 · see citing works

Specificity and mechanism of action of some commonly used protein kinase inhibitors

Davies, S., Reddy, H., Caivano, M., & Cohen, P. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510095 · Cited by 1,618 · see citing works

Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells

Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321 · see citing works

Wnt Signaling in Oncogenesis and Embryogenesis--a Look Outside the Nucleus

Peifer, M., & Polakis, P. (2000) · Science · doi:10.1126/science.287.5458.1606 · Cited by 1,253 · see citing works

GSK-3α regulates production of Alzheimer's disease amyloid-β peptides

Phiel, C. J., Wilson, C., Lee, V. M. ‐., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,200 · see citing works

The GSK3 hypothesis of Alzheimer’s disease

Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191 · see citing works

Lithium induces autophagy by inhibiting inositol monophosphatase

Sarkar, S., Floto, R. A., Berger, Z., Imarisio, S., Cordenier, A., Pasco, M., Cook, L. J., & Rubinsztein, D. C. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200504035 · Cited by 985 · see citing works

Hyperphosphorylation induces self-assembly of τ into tangles of paired helical filaments/straight filaments

Alonso, A. D. C., Zaidi, T., Novák, M., Grundke, I., & Iqbal, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121119298 · Cited by 968 · see citing works

Tau phosphorylation: the therapeutic challenge for neurodegenerative disease

Hanger, D. P., Anderton, B. H., & Noble, W. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.003 · Cited by 965 · see citing works

The neurobiological basis of spontaneous alternation

Lalonde, R. (2002) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00041-0 · Cited by 842 · see citing works

A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads

Braak, F., Braak, H., & Mandelkow, E. (1994) · Acta Neuropathologica · doi:10.1007/bf00293315 · Cited by 769 · see citing works

CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation

Petrucelli, L. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh083 · Cited by 735 · see citing works

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration <i>in vivo</i>

Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709 · see citing works

Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205

Goedert, M., Jakes, R., & Vanmechelen, E. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11484-e · Cited by 608 · see citing works

Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons

Chalecka-Franaszek, E., & Chuang, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8745 · Cited by 544 · see citing works

Molecular Targets of Lithium Action

Phiel, C. J., & Klein, P. S. (2001) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.789 · Cited by 513 · see citing works

Lithium Inhibits Glycogen Synthase Kinase-3 by Competition for Magnesium

Ryves, W. J., & Harwood, A. J. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.4169 · Cited by 495 · see citing works

Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404

Otvos, L., Feiner, L., Lang, E., Szendrei, G. I., Goedert, M., & Lee, V. M. (1994) · Journal of Neuroscience Research · doi:10.1002/jnr.490390607 · Cited by 488 · cited 1× · see citing works

The switch of tau protein to an Alzheimer‐like state includes the phosphorylation of two serine‐proline motifs upstream of the microtubule binding region.

Biernat, J., Mandelkow, E. M., Schröter, C., Lichtenberg‐Kraag, B., Steiner, B., Berling, B., Meyer, H., Mercken, M., Vandermeeren, A., & Goedert, M. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05204.x · Cited by 484 · see citing works

Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3

Hong, M., Chen, D. C. R., Klein, P. S., & Lee, V. M. ‐. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25326 · Cited by 470 · see citing works

CHIP-Hsc70 Complex Ubiquitinates Phosphorylated Tau and Enhances Cell Survival

Shimura, H., Schwartz, D., Gygi, S. P., & Kosik, K. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m305838200 · Cited by 469 · see citing works

Distribution of Active Glycogen Synthase Kinase 3β (GSK-3β) in Brains Staged for Alzheimer Disease Neurofibrillary Changes

Pei, J.-J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F. (1999) · Journal of Neuropathology &amp; Experimental Neurology · doi:10.1097/00005072-199909000-00011 · Cited by 459 · see citing works

Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases

Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459 · see citing works

Regulation of Akt and glycogen synthase kinase-3β phosphorylation by sodium valproate and lithium

Sarno, P. D., Li, X., & Jope, R. S. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00215-0 · Cited by 433 · see citing works

Differential Regulation of Glycogen Synthase Kinase 3β by Insulin and Wnt Signaling

Ding, V. W., Chen, R., & McCormick, F. P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005342200 · Cited by 428 · see citing works

Glycogen synthase kinase 3: a drug target for CNS therapies

Bhat, R. V., Haeberlein, S. L. B., & Ávila, J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02422.x · Cited by 408 · see citing works

Increased level of active GSK‐3β in Alzheimer’s disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration

Leroy, K., Yilmaz, Z., & Brion, J. ‐. (2007) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2006.00795.x · Cited by 404 · see citing works

Alzheimer's Disease-Like Tau Neuropathology Leads to Memory Deficits and Loss of Functional Synapses in a Novel Mutated Tau Transgenic Mouse without Any Motor Deficits

Schindowski, K., Bretteville, A., Leroy, K., Bégard, S., Brion, J., Hamdane, M., & Buée, L. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060002 · Cited by 396 · see citing works

Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein

Goedert, M., Jakes, R., Crowther, R. A., Cohen, P., Vanmechelen, E., Vandermeeren, M., & Cras, P. (1994) · Biochemical Journal · doi:10.1042/bj3010871 · Cited by 375 · see citing works

Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits

Holcomb, L. A., Gordon, M. N., Jantzen, P., Hsiao, K., Duff, K., & Morgan, D. (1999) · Behavior Genetics · doi:10.1023/a:1021691918517 · Cited by 353 · see citing works

Glycogen synthase kinase‐3 inhibition is integral to long‐term potentiation

Hooper, C., Markevich, V. A., Plattner, F., Killick, R., Schofield, E., Engel, T., Hernández, F., Anderton, B. H., Rosenblum, K., Bliss, T., et al. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05245.x · Cited by 345 · see citing works

Proteasomal degradation of tau protein

David, D. C., Layfield, R., Serpell, L., Narain, Y., Goedert, M., & Spillantini, M. G. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01137.x · Cited by 327 · see citing works

Lithium inhibits Alzheimer's disease‐like tau protein phosphorylation in neurons

Muñoz-Montaño, J. R., Moreno, F. J., Ávila, J., & Díaz‐Nido, J. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00688-1 · Cited by 322 · see citing works

Wnt signals are transmitted through N‐terminally dephosphorylated β‐catenin

Staal, F. J. T., van Noort, M., Strous, G. J., & Clevers, H. C. (2002) · EMBO Reports · doi:10.1093/embo-reports/kvf002 · Cited by 316 · see citing works

GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila

Mudher, A., Shepherd, D., Newman, T. A., Mildren, P., Jukes, J. P., Squire, A., Mears, A., Berg, S., MacKay, D., Asuni, A. A., et al. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001483 · Cited by 265 · see citing works

Developmental expression and localization of glycogen synthase kinase-3β in rat brain

Leroy, K., & Brion, J. (1999) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(99)00012-5 · Cited by 241 · see citing works

Chronic lithium administration to FTDP‐17 tau and GSK‐3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre‐formed neurofibrillary tangles do not revert

Engel, T., Goñi‐Oliver, P., Lucas, J. J., Avila, J., & Hernández, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04139.x · Cited by 223 · see citing works

Lithium Reduces Tau Phosphorylation but Not Aβ or Working Memory Deficits in a Transgenic Model with Both Plaques and Tangles

Caccamo, A., Oddo, S., Tran, L. X., & LaFerla, F. M. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.061178 · Cited by 218 · see citing works

In Vivo Evidence in the Brain for Lithium Inhibition of Glycogen Synthase Kinase-3

Gould, T. D., Chen, G. J., & Manji, H. K. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300283 · Cited by 217 · see citing works

Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model

Pérez, M., Hernández, F., Lim, F., Díaz‐Nido, J., & Ávila, J. (2003) · Journal of Alzheimer s Disease · doi:10.3233/jad-2003-5405 · Cited by 180 · see citing works

Tau in Alzheimer neurofibrillary tangles. N- and C-terminal regions are differentially associated with paired helical filaments and the location of a putative abnormal phosphorylation site

Brion, J., Hanger, D. P., Bruce, M. T., Couck, A. M., Flament-Durand, J., & Anderton, B. H. (1991) · Biochemical Journal · doi:10.1042/bj2730127 · Cited by 168 · see citing works

A feasibility and tolerability study of lithium in Alzheimer's disease

Macdonald, A., Briggs, K., Poppe, M., Higgins, A. R., Velayudhan, L., & Lovestone, S. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1964 · Cited by 159 · see citing works

Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations

Lovestone, S., Davis, D. R., Webster, M.-T., Kaech, S., Brion, J., Matus, A. I., & Anderton, B. H. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00183-8 · Cited by 157 · see citing works

The molecular basis of nephrogenic diabetes insipidus

Oksche, A., & Rosenthal, W. (1998) · Journal of Molecular Medicine · doi:10.1007/s001090050224 · Cited by 137 · see citing works

Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice

Leroy, K., Bretteville, A., Schindowski, K., Gilissen, E., Authelet, M., De Decker, R., Yilmaz, Z., Buée, L., & Brion, J.-P. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070345 · Cited by 135 · see citing works

Lithium: Clinical Considerations in Internal Medicine

Freeman, M. P., & Freeman, S. A. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.11.003 · Cited by 128 · see citing works

Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies

Nakashima, H., Ishihara, T., Suguimoto, S. P., Yokota, O., Oshima, E., Kugo, A., Terada, S., Hamamura, T., Trojanowski, J. Q., Lee, V. M. ‐., et al. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1087-4 · Cited by 119 · see citing works

Phosphorylation of tau protein by recombinant GSK‐3β: pronounced phosphorylation at select Ser/Thr‐Pro motifs but no phosphorylation at Ser262 in the repeat domain

Godemann, R., Biernat, J., Mandelkow, E., & Mandelkow�, E. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00741-3 · Cited by 110 · see citing works

A68 proteins in Alzheimer's disease are composed of several tau isoforms in a phosphorylated state which affects their electrophoretic mobilities

Brion, J., Hanger, D. P., Couck, A. M., & Anderton, B. H. (1991) · Biochemical Journal · doi:10.1042/bj2790831 · Cited by 109 · see citing works

The role of glycogen synthase kinase 3 in the early stages of Alzheimers’ disease

Hernández, F., & Ávila, J. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.10.026 · Cited by 86 · see citing works

Lithium and cognitive enhancement: leave it or take it?

Tsaltas, E., Kontis, D., Boulougouris, V., & Papadimitriou, G. N. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1311-8 · Cited by 56 · see citing works

Can Lithium or Valproate Untie Tangles in Alzheimer's Disease?

Tariot, P. N., & Aisen, P. S. S. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09com05331 · Cited by 53 · see citing works

Lithium treatment in Alzheimer’s disease does not promote cognitive enhancement, but may exert long-term neuroprotective effects

Pomara, N. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1510-y · Cited by 12 · see citing works

Evaluation of three simple methods for predicting therapeutic lithium doses

Srisurapanont, M., Pratoomsri, W., & Maneeton, N. (2000) · Psychiatry Research · doi:10.1016/s0165-1781(00)00133-5 · Cited by 11 · see citing works

Development of an automated photometric assay for serum lithium and use of binding equilibrium expressions to optimize results

Thompson, J. C. (2002) · Clinica Chimica Acta · doi:10.1016/s0009-8981(02)00368-6 · Cited by 6 · see citing works

Alzheimer's disease

Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336 · see citing works

Roles of tau protein in health and disease

Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003 · see citing works

Post-translational modifications of tau protein: Implications for Alzheimer's disease

Martin, L., Latypova, X., & Terro, F. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2010.12.023 · Cited by 645 · see citing works

Therapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder

Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404 · see citing works

Neuroprotective Effects of Lithium: Implications for the Treatment of Alzheimer’s Disease and Related Neurodegenerative Disorders

Forlenza, O. V., de Paula, V. D. J. R., & Diniz, B. S. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn5000309 · Cited by 333 · see citing works

Insulin Resistance and Neurodegeneration: Progress towards the Development of New Therapeutics for Alzheimer's Disease

de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331 · see citing works

Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease

Golpich, M., Amini, E., Hemmati, F., Ibrahim, N. M., Rahmani, B., Mohamed, Z., Raymond, A. A., Dargahi, L., Ghasemi, R., & Ahmadiani, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.010 · Cited by 276 · see citing works

Animal models in the drug discovery pipeline for Alzheimer's disease

Dam, D. V., & Deyn, P. P. D. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01299.x · Cited by 228 · see citing works

Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders

Chiu, C., & Chuang, D. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.07.006 · Cited by 227 · see citing works

“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies

Xia, Y., Prokop, S., & Giasson, B. I. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00460-5 · Cited by 218 · see citing works

GSK‐3 in Neurodegenerative Diseases

Lei, P., Ayton, S., Bush, A. I., & Adlard, P. A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/189246 · Cited by 177 · see citing works

Revisiting the grammar of Tau aggregation and pathology formation: how new insights from brain pathology are shaping how we study and target Tauopathies

Limorenko, G., & Lashuel, H. A. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00127b · Cited by 162 · see citing works

Lack of Tau Proteins Rescues Neuronal Cell Death and Decreases Amyloidogenic Processing of APP in APP/PS1 Mice

Leroy, K., Ando, K., Laporte, V., Dedecker, R., Suain, V., Authelet, M., Héraud, C., Pierrot, N., Yilmaz, Z., Octave, J.-N., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.08.012 · Cited by 161 · see citing works

Lithium: the pharmacodynamic actions of the amazing ion

Brown, K. M., & Tracy, D. K. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312471963 · Cited by 140 · see citing works

New Insights Into Drug Discovery Targeting Tau Protein

Soeda, Y., & Takashima, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.590896 · Cited by 133 · see citing works

Therapeutic strategies for tau mediated neurodegeneration

Yoshiyama, Y., Lee, V. M. ‐., & Trojanowski, J. Q. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303144 · Cited by 129 · see citing works

Lithium deficiency and the onset of Alzheimer’s disease

Aron, L., Ngian, Z., Qiu, C., Choi, J., Liang, M., Drake, D., Hamplova, S. E., Lacey, E. K., Roche, P., Yuan, M., et al. (2025) · Nature · doi:10.1038/s41586-025-09335-x · Cited by 141 · see citing works

Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders

Diniz, B., Machado-Vieira, R., & Forlenza (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s33086 · Cited by 128 · see citing works

Amyloid-β pathology enhances pathological fibrillary tau seeding induced by Alzheimer PHF in vivo

Vergara, C., Houben, S., Suain, V., Yilmaz, Z., Decker, R. D., Dries, V. V., Boom, A., Mansour, S., Leroy, K., Ando, K., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1953-5 · Cited by 125 · see citing works

Functional Implications of Glycogen Synthase Kinase‐3‐Mediated Tau Phosphorylation

Hanger, D. P., & Noble, W. J. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/352805 · Cited by 118 · see citing works

Amyloid β-Exposed Human Astrocytes Overproduce Phospho-Tau and Overrelease It within Exosomes, Effects Suppressed by Calcilytic NPS 2143—Further Implications for Alzheimer's Therapy

Chiarini, A., Armato, U., Gardenal, E., Gui, L., & Prà, I. D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00217 · Cited by 102 · see citing works

From tau phosphorylation to tau aggregation: what about neuronal death?

Buée, L., Troquier, L., Burnouf, S., Bélarbi, K., der Jeugd, A. V., Ahmed, T., Fernández-Gómez, F.-J., Caillierez, R., Grosjean, M., Bégard, S., et al. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380967 · Cited by 99 · see citing works

Diet and lifestyle impact the development and progression of Alzheimer’s dementia

Arora, S., Santiago, J. A., Bernstein, M., & Potashkin, J. A. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1213223 · Cited by 96 · see citing works

Lithium suppression of tau induces brain iron accumulation and neurodegeneration

Lei, P., Ayton, S., Appukuttan, A. T., Moon, S., Duce, J. A., Volitakis, I., Cherny, R. A., Wood, S. J., Greenough, M. A., Berger, G. E., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.96 · Cited by 89 · see citing works

Neuroprotective effect of quercetin nanoparticles: A possible prophylactic and therapeutic role in alzheimer’s disease

Rifaai, R. A., Mokhemer, S. A., Saber, E. A., El‐Aleem, S. A. A., & El‐Tahawy, N. F. G. (2020) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2020.101795 · Cited by 88 · see citing works

Invited review: Animal models of tauopathies and their implications for research/translation into the clinic

Dujardin, S., Colin, M., & Buée, L. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12200 · Cited by 88 · see citing works

Protein kinases in neurodegenerative diseases: current understandings and implications for drug discovery

Wu, X., Yang, Z., Zou, J., Gao, H., Shao, Z., Li, C., & Lei, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02179-x · Cited by 88 · see citing works

Accelerated Human Mutant Tau Aggregation by Knocking Out Murine Tau in a Transgenic Mouse Model

Ando, K., Leroy, K., Héraud, C., Yilmaz, Z., Authelet, M., Suain, V., Decker, R. D., & Brion, J. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.10.034 · Cited by 80 · see citing works

Increased misfolding and truncation of tau in APP/PS1/tau transgenic mice compared to mutant tau mice

Héraud, C., Goufak, D., Ando, K., Leroy, K., Suain, V., Yilmaz, Z., De Decker, R., Authelet, M., Laporte, V., Octave, J.-N., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.010 · Cited by 80 · see citing works

A Role for WNT/β-Catenin Signaling in the Neural Mechanisms of Behavior

Maguschak, K. A., & Ressler, K. J. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-012-9350-7 · Cited by 78 · see citing works

Neuroprotective action of lithium in disorders of the central nervous system.

Chiu, C., & Chuang, D. (2011) · PubMed · doi:10.3969/j.issn.1672-7347.2011.06.001 · Cited by 78 · see citing works

GSK3 as a Sensor Determining Cell Fate in the Brain

Cole, A. R. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00004 · Cited by 76 · see citing works

Current perspectives on pharmacotherapy of Alzheimer's disease

Chopra, K., Misra, S., & Kuhad, A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.520702 · Cited by 74 · see citing works

Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments

Sales, T. A., Prandi, I. G., de Castro, A. A., Leal, D. H. S., da Cunha, E. F. F., Kuča, K., & Ramalho, T. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081829 · Cited by 73 · see citing works

The dynamic role of beta-catenin in synaptic plasticity

Maguschak, K. A., & Ressler, K. J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.032 · Cited by 72 · see citing works

Reduction of Glucose Metabolism in Olfactory Bulb is an Earlier Alzheimer's Disease-related Biomarker in 5XFAD Mice

Xiao, N., Zhang, J., Zhou, M., Wei, Z., Wu, X., Dai, X., Zhu, Y., & Chen, X. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.162507 · Cited by 69 · see citing works

High–Molecular-Weight Paired Helical Filaments from Alzheimer Brain Induces Seeding of Wild-Type Mouse Tau into an Argyrophilic 4R Tau Pathology in Vivo

Audouard, E., Houben, S., Masaracchia, C., Yilmaz, Z., Suain, V., Authelet, M., Decker, R. D., Buée, L., Boom, A., Leroy, K., et al. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.06.008 · Cited by 68 · see citing works

The association between lithium use and neurocognitive performance in patients with bipolar disorder

Burdick, K. E., Millett, C. E., Russo, M., Alda, M., Alliey‐Rodriguez, N., Anand, A., Balaraman, Y., Berrettini, W. H., Bertram, H. S., Calabrese, J. R., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0683-2 · Cited by 69 · see citing works

Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study

Wahlqvist, M. L., Lee, M.-S., Chuang, S., Hsu, C., Tsai, H.-N., Yu, S.-H., & Chang, H. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-150 · Cited by 62 · see citing works

Wnt and lithium: a common destiny in the therapy of nervous system pathologies?

Meffre, D., Grenier, J., Bernard, S., Courtin, F., Dudev, T., Shackleford, G., Jafarian-Tehrani, M., & Massaad, C. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1378-1 · Cited by 61 · see citing works

Enhancing a Wnt-Telomere Feedback Loop Restores Intestinal Stem Cell Function in a Human Organotypic Model of Dyskeratosis Congenita

Woo, D., Chen, Q., Yang, T.-L., Glineburg, M. R., Hoge, C., Leu, N. A., Johnson, F. B., & Lengner, C. J. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.05.024 · Cited by 61 · see citing works

Clinical Perspectives of Lithium’s Neuroprotective Effect

RYBAKOWSKI, J. K., Suwalska, A., & Hájek, T. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-124436 · Cited by 58 · see citing works

New and emerging treatments for Alzheimer’s disease

Corbett, A., Smith, J. S., & Ballard, C. G. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.43 · Cited by 56 · see citing works

Progressive Age-Related Cognitive Decline in Tau Mice

der Jeugd, A. V., Vermaercke, B., Derisbourg, M. J., Lo, A. C., Hamdane, M., Blum, D. L., Buée, L., & D’Hooge, R. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130110 · Cited by 54 · see citing works

Lithium in neuropsychiatry: A 2010 update

RYBAKOWSKI, J. K. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.559274 · Cited by 52 · see citing works

Hyperphosphorylated tau is implicated in acquired epilepsy and neuropsychiatric comorbidities.

Zheng, P., Shultz, S. R., Hovens, C. M., Velakoulis, D., Jones, N. C., & O’Brien, T. J. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8601-9 · Cited by 48 · see citing works

Unfolded protein response activates glycogen synthase kinase-3 via selective lysosomal degradation

Nijholt, D. A. T., Nölle, A., van Haastert, E. S., Edelijn, H., Toonen, R. F. G., Hoozemans, J. J. M., & Scheper, W. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.01.008 · Cited by 48 · see citing works

Advances in tau-based drug discovery

Noble, W. J., Pooler, A. M., & Hanger, D. P. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.586690 · Cited by 44 · see citing works

Is There Justification to Treat Neurodegenerative Disorders by Repurposing Drugs? The Case of Alzheimer’s Disease, Lithium, and Autophagy

Damri, O., Shemesh, N., & Agam, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010189 · Cited by 42 · see citing works

Antiviral, immunomodulatory, and neuroprotective effect of lithium

RYBAKOWSKI, J. K. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2102068 · Cited by 42 · see citing works

Molecular mechanisms and therapeutic potential of lithium in Alzheimer’s disease: repurposing an old class of drugs

Shen, Y., Zhao, M., Zhao, P., Meng, L., Zhang, Y., Zhang, G., Taishi, Y., & Sun, L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1408462 · Cited by 43 · see citing works

Targeting neurodegeneration to prevent post-traumatic epilepsy.

Ali, I., Silva, J. C., Liu, S., Shultz, S. R., Kwan, P., Jones, N. C., & O'Brien, T. J. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.006 · Cited by 38 · see citing works

GSK-3β and memory formation

Takashima, A. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00047 · Cited by 38 · see citing works

Tauopathy and Epilepsy Comorbidities and Underlying Mechanisms

Hwang, K., Vaknalli, R. N., Addo-Osafo, K., Vicente, M., & Vossel, K. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.903973 · Cited by 35 · see citing works

In vitro modelling of Alzheimer's disease: Degeneration and cell death induced by viral delivery of amyloid and tau

Stoppelkamp, S., Bell, H. S., Palacios-Filardo, J., Shewan, D. A., Riedel, G., & Platt, B. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.01.018 · Cited by 34 · see citing works

New and emerging treatments for Alzheimer's disease

Corbett, A., & Ballard, C. G. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.675327 · Cited by 26 · see citing works

Macroautophagy and Mitophagy in Neurodegenerative Disorders: Focus on Therapeutic Interventions

Magalhães, J. D., Fão, L., Vilaça, R., Cardoso, S. M., & Rego, A. C. (2021) · Biomedicines · doi:10.3390/biomedicines9111625 · Cited by 27 · see citing works

Herbs to curb cyclic nucleotide phosphodiesterase and their potential role in Alzheimer’s disease

Kumar, A., Sharma, V., Singh, V. P., Kaundal, M., Gupta, M., Bariwal, J. B., & Deshmukh, R. R. (2015) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2015.05.009 · Cited by 27 · see citing works

Therapeutic modulation of neurogenesis to improve hippocampal plasticity and cognition in aging and Alzheimer's disease

MOSTAFA, M., Disouky, A., & Lazarov, O. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00580 · Cited by 28 · see citing works

Hyperphosphorylation of tau by GSK-3β in Alzheimer’s disease: The interaction of Aβ and sphingolipid mediators as a therapeutic target

Jembrek, M. J., Leko, M. B., Pivac, N., Hof, P. R., & Šimić, G. (2013) · Translational Neuroscience · doi:10.2478/s13380-013-0144-z · Cited by 25 · see citing works

Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease

Stancu, I., Ferraiolo, M., Terwel, D., & Dewachter, I. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_13 · Cited by 23 · see citing works

Recent advances in tau-directed immunotherapy against Alzheimer’s disease: an overview of pre-clinical and clinical development

Ng, P. Y., Chang, I. S., Koh, R. Y., & Chye, S. M. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00591-6 · Cited by 24 · see citing works

The next step of neurogenesis in the context of Alzheimer’s disease

Moradi, H. R., Hajali, V., Khaksar, Z., Vafaee, F., Forouzanfar, F., & Negah, S. S. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06520-9 · Cited by 20 · see citing works

Dementia Therapy Targeting Tau

Buée, L. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_30 · Cited by 18 · see citing works

Amyloid beta 25–35 impairs reconsolidation of object recognition memory in rats and this effect is prevented by lithium carbonate

Álvarez-Ruíz, Y., & Carrillo-Mora, P. U. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.06.003 · Cited by 16 · see citing works

Genetic ablation of tau in postnatal neurons rescues decreased adult hippocampal neurogenesis in a tauopathy model

Houben, S., Leroy, K., Ando, K., Yilmaz, Z., Widomski, C., Buée, L., & Brion, J. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.02.021 · Cited by 15 · see citing works

Lithium: An Old Drug for New Therapeutic Strategy for Alzheimer’s Disease and Related Dementia

Shim, S. S., Berglund, K., & Yu, S. P. (2023) · Neurodegenerative Diseases · doi:10.1159/000533797 · Cited by 13 · see citing works

Modulation of tau pathology in tau transgenic models

Brion, J., Ando, K., Héraud, C., & Leroy, K. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380996 · Cited by 11 · see citing works

Chronic Lithium Treatment in a Rat Model of Basal Forebrain Cholinergic Depletion: Effects on Memory Impairment and Neurodegeneration

Gelfo, F., Cutuli, D., Nobili, A., Bartolo, P. D., D’Amelio, M., Petrosini, L., & Caltagirone, C. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160892 · Cited by 10 · see citing works

Roles of Glycogen Synthase Kinase-3 in Alzheimer's Disease: From Pathology to Treatment Target

Liu, H., Leu, S., & Chuang, D. (2012) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2012.04.001 · Cited by 9 · see citing works

Cellular model of Alzheimer's disease — Relevance to therapeutic testing

Marwarha, G., & Ghribi, O. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.11.011 · Cited by 8 · see citing works

Commentary: Corroboration of a Major Role for Herpes Simplex Virus Type 1 in Alzheimer's Disease

RYBAKOWSKI, J. K. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00433 · Cited by 8 · see citing works

Potential Disease-Modifying Effects of Lithium Carbonate in Niemann-Pick Disease, Type C1

Han, S., Zhang, H., Yi, M., Liu, X., Maegawa, G. H. B., Zou, Y., Wang, Q., Wu, D., & Ye, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.667361 · Cited by 7 · see citing works

Animal Models of Acquired Epilepsy and Tauopathies

Zheng, P., Shultz, S. R., Hovens, C. M., & O'Brien, T. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804066-9.00072-9 · Cited by 7 · see citing works

Metals in medicine: unlocking new avenues for neurodegenerative disease treatment

Tan, K. T., Cheong, K. W., Wong, L. C., Bertrand, H. C., Karim, N. H. A., Chong, Y. K., & Low, M. L. (2025) · Frontiers in Chemical Biology · doi:10.3389/fchbi.2025.1696058 · Cited by 6 · see citing works

Tau Phosphorylation and μ-Calpain Activation Mediate the Dexamethasone-Induced Inhibition on the Insulin-Stimulated Akt Phosphorylation

Liu, Y., Su, Y., Sun, S., Wang, T., Qiao, X., Run, X., & Liang, Z. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035783 · Cited by 6 · see citing works

The Role of Tau Protein in Diseases

Das Bhaskar, C. (2018) · Annals of Advances in Chemistry · doi:10.29328/journal.aac.1001010 · Cited by 6 · see citing works

Frontotemporal dementia

Wauters, E., Sleegers, K., Cruts, M., & Broeckhoven, C. V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805120-7.00009-9 · Cited by 5 · see citing works

Comment les acteurs moléculaires de la pathologie Alzheimer permettent de comprendre la démence ? Quelles conséquences diagnostiques et thérapeutiques ?

Buée, L., Blum, D. L., Bombois, S., Buée‐Scherrer, V., Caillet‐Boudin, M., Colin, M., Deramecourt, V., Dhaenens, C., Galas, M., Hamdane, M., et al. (2010) · Therapies · doi:10.2515/therapie/2010054 · Cited by 4 · see citing works

Potential neuroprotective strategies against tauopathy

Wheeler, J. M., Guthrie, C. R., & Kraemer, B. C. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120017 · Cited by 4 · see citing works

Stimulation of Tau Degradation

Quintanilla, R. A., Cabezas-Opazo, F., Pallo, S. P., Chesser, A. S., & Johnson, G. V. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00013-7 · Cited by 3 · see citing works

Animal Models of Alzheimer's Disease

Bharadwaj, P. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch10 · Cited by 3 · see citing works

Lithium: effects in animal models of vanishing white matter are not promising

Witkamp, D., Oudejans, E., Hoogterp, L., Hu‐A‐Ng, G. V., Glaittli, K. A., Stevenson, T. J., Huijsmans, M., Abbink, T. E. M., van der Knaap, M. S., & Bonkowsky, J. L. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1275744 · Cited by 2 · see citing works

Mood Stabilizers: Lithium

RYBAKOWSKI, J. K. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_45-1 · Cited by 2 · see citing works

[Proposal of new trace elements classification to be used in nutrition, oligotherapy and other therapeutics strategies].

Hernández, J. R., Bonete, M.-J., & Martínez‐Espinosa, R. M. (2014) · PubMed · doi:10.3305/nh.2015.31.3.8325 · Cited by 2 · see citing works

Gut–Brain Axis: Role of Gut Microbiota in Neurodegenerative Disease

Narang, A., & Sandhir, R. (2022) · Springer eBooks · doi:10.1007/978-981-16-6760-2_1 · Cited by 1 · see citing works

Lithium mitigates hippocampal tau pathology in a rodent model of traumatic brain injury

Donison, N. S., Palik, J., Hintermayer, M. A., Volkening, K., & Strong, M. J. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02170-1 · Cited by 1 · see citing works

Mood Stabilizers: Lithium

RYBAKOWSKI, J. K. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_45 · Cited by 1 · see citing works

Toxic Tau Aggregation in AD

Zaafar, D. K. (2023) · Springer eBooks · doi:10.1007/978-981-19-3949-5_43-1 · Cited by 1 · see citing works

[Transgenic animals: uses and limitations in the 21st century medicine].

Cavagnari, B. M. (2010) · PubMed · doi:10.1590/s0325-00752010000400009 · Cited by 1 · see citing works

Ação de agonistas da via Wnt/beta-catenina em células T CD4+ murinas

dos Santos, C. C. C. (2015) · doi:10.11606/d.5.2015.tde-26082015-110639

THE POTENTIAL OF AUTOPHAGY REGULATION IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

Winslow, A. R., Green-Thompson, Z. W., & Rubinsztein, D. C. (2012) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814350457_0013

Lithium and Alzheimer’s Disease: Experimental, Epidemiological, and Clinical Findings

RYBAKOWSKI, J. K. (2018) · InTech eBooks · doi:10.5772/intechopen.74239

Autophagic Dysfunction in Neurodegeneration

Kaira, M., Ahlawat, A., Walia, V., & Garg, M. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-1317-0.ch002

Consequences of Non-physiological Ligands Binding to DREAM on Its Secondary and Tertiary Structures and Interactions with Intracellular Partners.

Azam, S. (2019) · doi:10.25148/etd.fidc008837

Faculty Opinions recommendation of Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for alzheimer's disease.

Rosenzweig, S. A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727123638.793572332

Oral administration of lithium chloride ameliorate spinal cord injury-induced hyperalgesia in male rats

Rahimi, G., Mirsadeghi, S., Rahmani, S., Izadi, A., Ghodsi, Z., Ghodsi, S. M., Rahimi‐Movaghar, V., & Kiani, S. (2022) · PharmaNutrition · doi:10.1016/j.phanu.2022.100307

Toxic Tau Aggregation in AD

Zaafar, D. K. (2024) · Springer eBooks · doi:10.1007/978-981-99-7557-0_43

Implication du complexe récepteur 5-HT4/APP/ADAM10 dans la voie non-amyloïdogénique de la maladie d’Alzheimer

Cochet, M. (2011) · theses.fr (ABES) · doi:10.70675/599a8bbez3c0bz407dzbd52z0872ed5f8f6d

Impact de l’infection à Helicobacter pylori sur la maladie d’Alzheimer

Baudron, C. R. (2014) · theses.fr (ABES) · doi:10.70675/201f68e4z646cz4e66z80e2zd8a4b726fbe7

O4‐01–07: Subacute per OS lithium treatment decreases Tau phosphorylation and neurofibrillary tangles load in G272V/P301S mutant Tau transgenic mice

Brion, J., Leroy, K., Ando, K., Bretteville, A., Yilmaz, Z., Authelet, M., Dedecker, R., & Buée, L. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.506

Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model

Pérez, M., Hernández, F., Lim, F., Díaz‐Nido, J., & Ávila, J. (2003) · Journal of Alzheimer s Disease · doi:10.3233/jad-2003-5405 · Cited by 180 · see citing works

P4–334: Chronic oral lithium administration attenuates motor disturbance through reducing tau phosphorylation in a tauopathy model mice

Motoi, Y., Shimada, K., Ishiguro, K., Shinohara, A., Chiba, M., & Mizuno, Y. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.05.2075

Chronic lithium administration to FTDP‐17 tau and GSK‐3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre‐formed neurofibrillary tangles do not revert

Engel, T., Goñi‐Oliver, P., Lucas, J. J., Avila, J., & Hernández, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04139.x · Cited by 223 · see citing works

P2‐536: Long‐term oral lithium treatment attenuates motor disturbance by promoting autophagy in tauopathy model mice

Shimada, K. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.1405 · Cited by 1 · see citing works